Biogen Inc. ($BIIB) Stock Forecast: Up 6.6% Today

What is Biogen Inc.?

Biogen Inc. (BIIB) is a renowned biotechnology company known for its innovative treatments in neurology, immunology, and rare diseases. The company has been making significant strides in its product pipeline and financial performance.

Why is Biogen Inc. going up?

BIIB stock is up 6.6% on Apr 29, 2026 18:41

• BIIB stock experienced a strong bullish movement following the company's impressive Q1 earnings report, surpassing both earnings per share (EPS) and revenue estimates.
• The announcement of Biogen's plans to acquire Apellis Pharmaceuticals for $5.6 billion further boosted investor confidence in the company's growth strategy and expansion of its portfolio.
• Despite the positive performance, Biogen revised its full-year earnings outlook downwards due to increased costs associated with business development activities, signaling a cautious approach amidst its ambitious growth plans.
• The market's reaction indicates that investors are optimistic about Biogen's future prospects, driven by its strong financial performance and strategic acquisitions in the biopharmaceutical sector.

BIIB Price Chart

BIIB Technical Analysis

BIIB News

Apellis earnings up next: Last report before Biogen takeover?

Apellis Pharmaceuticals is set to report its first-quarter earnings, which could be its last as an independent company before Biogen completes its $5.6 billion acquisition. Analysts anticipate a loss of 34 cents per share on revenue of $203.6 million, a reversal from the previous quarter's surprise profit. Investors will be seeking updates on the acquisition timeline and regulatory clearances, as well as insights into Syfovre sales trends and potential contingent value rights payouts.

https://www.investing.com/news/earnings/apellis-earnings-up-next-last-report-before-biogen-takeover-93CH-4646402

Biogen Inc. (BIIB) Tops Q1 Earnings and Revenue Estimates

Biogen Inc. (BIIB) exceeded Q1 earnings and revenue estimates, reporting $3.57 EPS against an expected $2.95 and revenues of $2.48 billion against a $2.25 billion estimate. The company has consistently surpassed both EPS and revenue expectations over the past four quarters. Despite this strong performance, Biogen's stock has performed similarly to the S&P 500 year-to-date, and currently holds a Zacks Rank #3 (Hold) anticipation for future market performance.

https://finance.yahoo.com/sectors/healthcare/articles/biogen-inc-biib-tops-q1-111002590.html

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Ionis Pharmaceuticals reported strong first-quarter 2026 financial results, with total revenue increasing by 87% year-over-year, driven by commercial success of TRYNGOLZA and DAWNZERA, and substantial R&D revenue. The company increased its annual TRYNGOLZA peak net sales guidance to over $3 billion for severe hypertriglyceridemia (sHTG) and improved its 2026 financial outlook, anticipating two additional independent launches for olezarsen (sHTG) and zilganersen (Alexander disease). Ionis also highlighted progress in its partnered programs, including positive Phase 3 data for bepirovirsen in chronic hepatitis B and upcoming results for pelacarsen and eplontersen.

https://www.businesswire.com/news/home/20260429109051/en/Ionis-reports-first-quarter-2026-financial-results-and-highlights-progress-on-key-programs

Biogen (NASDAQ: BIIB) boosts profit and cash flow, plans $5.6B Apellis buy

Biogen (NASDAQ: BIIB) reported a significant increase in its Q1 2026 profits and cash flow, with revenue rising to $2.48 billion and net income attributable to Biogen increasing to $319.5 million. The company announced plans to acquire Apellis Pharmaceuticals for approximately $5.6 billion, including a contingent value right, aiming to expand its immunology and rare disease portfolio. Biogen also highlighted key developments in its product pipeline, including positive clinical trial results for litifilimab and regulatory approvals for high-dose SPINRAZA, alongside ongoing macroeconomic and regulatory challenges.

https://www.stocktitan.net/sec-filings/BIIB/10-q-biogen-inc-quarterly-earnings-report-04e0adc80293.html

Biogen posts Q1 beat, trims earnings outlook (BIIB:NASDAQ)

Biogen (BIIB) reported first-quarter results that surpassed analyst estimates. However, the company revised its full-year earnings forecast downwards, attributing the adjustment to costs associated with its business development activities aimed at supporting its growth strategy. Biogen is an Alzheimer's drug developer.

https://seekingalpha.com/news/4581377-biogen-posts-q1-beat-trims-earnings-outlook

Trending Today

Novavax Inc. ($NVAX) Stock Forecast: Down 7.6% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 6.1% Today

Ubiquiti ($UI) Stock Forecast: Down 6.8% Today

Corsair Gaming Inc. ($CRSR) Stock Forecast: Down 3.1% Today

Draftkings Inc ($DKNG) Stock Forecast: Up 5.2% Today

Chemours Company (The) ($CC) Stock Forecast: Down 5.2% Today

Teleflex Incorporated ($TFX) Stock Forecast: Up 7.9% Today

Fortinet Inc. ($FTNT) Stock Forecast: Up 20.9% Today

PTC Inc. ($PTC) Stock Forecast: Up 9.9% Today

Datadog Inc. ($DDOG) Stock Forecast: Up 31.4% Today

Biogen Inc. Price History

31.02.2026 - BIIB Stock was down 5.6%

• The bearish movement in Biogen's stock price is possibly linked to the market's response to its acquisition of Apellis Pharmaceuticals for $5.6 billion. Concerns from analysts regarding the premium paid and competitive environment could be contributing to investor skepticism, despite the potential advantages of acquiring two approved medications and expertise in the nephrology sector.
• Biogen's strategic move to diversify its product portfolio and hasten the market entry of its new kidney disease drug, felzartamab, through the acquisition of Apellis Pharmaceuticals might be facing uncertainty from the market in terms of immediate financial impact and long-term growth prospects.
• The surge in Apellis Pharmaceuticals' stock value following the acquisition announcement presents a positive market sentiment toward the deal, contrasting with the volatility in Biogen's stock price. This disparity in market reactions between the two companies involved could be influencing Biogen's stock movement.
• Investors interested in Biogen are likely keeping a close watch on the company's future financial reports and strategic initiatives to evaluate the success of the acquisition and its potential effects on Biogen's overall performance in upcoming quarters.

31.02.2026 - BIIB Stock was down 5.0%

• Biogen's bearish movement today could be attributed to the announcement of its acquisition of Apellis Pharmaceuticals for $5.6 billion. While acquisitions are often seen as a strategic move to expand the company's portfolio, the market may have reacted negatively due to concerns about the integration process and the potential impact on Biogen's financials.
• The news of Stryker promoting key finance executives may have also influenced investor sentiment, as leadership changes within a company can sometimes create uncertainty about future financial strategies and performance.
• Additionally, the overall market sentiment towards biotech stocks and the broader economic conditions could have contributed to the bearish movement in Biogen's stock today. Investors may be cautious amid market volatility and global economic uncertainties.

31.02.2026 - BIIB Stock was down 5.2%

• Biogen's stock experienced a bearish movement as the market reacted negatively to the news of its intent to acquire Apellis Pharmaceuticals for $5.6 billion.
• The acquisition is seen as a strategic move to enhance Biogen's immunology and rare disease portfolio with Apellis's FDA-approved therapies, but investors may have concerns about the hefty price tag and potential integration challenges.
• The market might be cautious about the impact of this acquisition on Biogen's financials, revenue, and adjusted earnings per share starting in 2027, leading to the bearish trend.
• Investors are likely monitoring how Biogen navigates this acquisition and integrates Apellis's assets into its existing portfolio to gauge the long-term impact on the company's growth prospects.

27.02.2026 - BIIB Stock was down 2.5%

• The decline in Biogen's stock value possibly stemmed from Vanguard's recent disclosure of holding zero shares and beneficial ownership of Biogen. This change in investment interest could have prompted investor apprehension, leading to a sell-off.
• Positive growth predictions in the Anca Vasculitis Drug Market and emerging therapies in the Spinal Muscular Atrophy Pipeline might have momentarily diverted investor attention from Biogen, negatively affecting its stock performance.
• The financial outcomes and strategic advancements reported by MapLight Therapeutics, such as upcoming Phase 2 study outcomes, may have redirected investor focus towards other biotech firms, influencing Biogen's stock downward.
• Although the collaboration between Biogen and Alteogen Inc. presented optimistic prospects for Biogen, it might not have sufficed to counter prevailing market sentiments and incite a bullish upturn in the stock on the given day.

06.01.2026 - BIIB Stock was up 2.4%

• BIIB stock surged today, hitting a 52-week high at $190.34, marking a 31.14% rise in the past year and a 43.31% gain in the last six months.
• The positive market response follows Biogen's strong Q4 2025 financial performance, surpassing revenue projections and beating analyst estimates for non-GAAP EPS.
• Biogen's strategic focus on its at-home Alzheimer’s drug, successful trial outcomes for multiple treatments, and receipt of FDA Breakthrough Therapy Designation have boosted investor confidence in the company's future growth prospects.
• Despite revenue challenges from declining multiple sclerosis treatments, Biogen's optimistic 2026 outlook, emphasis on neurodegenerative and rare diseases, and favorable valuation based on financial metrics have bolstered investor trust and fueled the stock's upward trajectory.

06.01.2026 - BIIB Stock was up 6.9%

• Biogen's stock demonstrated significant upward momentum, reaching a 52-week high, following the release of impressive fourth-quarter earnings and revenues, attributed to the notable sales growth of its Alzheimer's medication Leqembi.
• The company's strategic shift from a primary emphasis on multiple sclerosis to establishing itself as a key player in neuro-innovation, with successful treatments like Skyclarys and Leqembi, has amplified investor confidence and positively impacted the stock's performance.
• Biogen's perceived undervaluation, evidenced by a P/E ratio of 16.92 and a robust free cash flow yield of 8%, alongside favorable developments such as FDA recognitions and successful trial outcomes, has further bolstered the optimistic outlook surrounding the stock.
• Biogen's adept navigation of obstacles, including regulatory complexities and market competition, in conjunction with its growth-oriented approach through collaborations and a diversified product pipeline, highlights its potential for long-term success in the dynamic biopharmaceutical sector.

06.01.2026 - BIIB Stock was up 5.3%

• Despite a decrease in revenue from multiple sclerosis treatments, Biogen posted strong financial results for Q4 and full year 2025, thanks to growth products such as LEQEMBI, SKYCLARYS, and ZURZUVAE.
• Investors reacted positively to the company's overall performance and growth in newer products, leading to a bullish movement in the stock despite the decline in revenue from multiple sclerosis treatments.
• Biogen's emphasis on expanding its pipeline through acquisitions and collaborations, as well as achieving important regulatory milestones, has instilled optimism among investors despite challenges in its multiple sclerosis product portfolio.
• The market movement demonstrates investor trust in Biogen's capability to navigate competition, regulatory changes, and operational risks while fostering growth through innovative products and strategic initiatives.

25.01.2026 - BIIB Stock was down 2.5%

• The downward trend in BIIB's stock price today may be linked to a trade secrets lawsuit and a dismissal motion filed by Definium Therapeutics Inc., resulting in uncertainty and legal concerns.
• Market sentiment could also be influenced by the struggles of other biotech firms such as Avidity Biosciences, which reported significant financial losses, leading to doubts about the sector's financial performance and future growth.
• Furthermore, the FDA's rejection of Alvotech's biologics license application due to facility issues and the subsequent legal investigation could have raised apprehensions about regulatory challenges in the biotech industry, impacting attitudes towards companies like BIIB.

29.03.2026 - BIIB Stock was up 5.5%

• Biogen Inc. (BIIB) surpassed Q1 earnings and revenue expectations, indicating strong financial performance.
• The company's recent announcement to acquire Apellis Pharmaceuticals for $5.6 billion illustrates strategic expansion strategies.
• Despite revising its earnings guidance downwards, Biogen's favorable clinical trial outcomes and regulatory approvals suggest ongoing growth opportunities.
• The market sentiment towards BIIB may have benefited from Ionis Pharmaceuticals' successful initiatives such as TRYNGOLZA and DAWNZERA, given the companies' shared emphasis on innovative therapies.

29.03.2026 - BIIB Stock was up 6.6%

• BIIB stock experienced a strong bullish movement following the company's impressive Q1 earnings report, surpassing both earnings per share (EPS) and revenue estimates.
• The announcement of Biogen's plans to acquire Apellis Pharmaceuticals for $5.6 billion further boosted investor confidence in the company's growth strategy and expansion of its portfolio.
• Despite the positive performance, Biogen revised its full-year earnings outlook downwards due to increased costs associated with business development activities, signaling a cautious approach amidst its ambitious growth plans.
• The market's reaction indicates that investors are optimistic about Biogen's future prospects, driven by its strong financial performance and strategic acquisitions in the biopharmaceutical sector.

14.00.2026 - BIIB Stock was down 5.3%

• The downward movement in Biogen's stock is likely due to expected expenses in the fourth quarter related to in-process research and development (IPR&D) and milestone payments, impacting earnings per share.
• Despite introducing Leqembi and exploring new Alzheimer's treatments, the market response is pessimistic towards the predicted financial changes and costs.
• Analysts, including Bank of America Securities' Hold rating, may be influencing the bearish outlook as investors evaluate the company's financial prospects alongside its strategic goals and product advancements.

14.00.2026 - BIIB Stock was down 6.0%

• Today's downturn in BIIB stock is linked to an anticipated impact of about $1.26 per share on earnings due to research and development charges in the fourth quarter.
• Despite efforts to enhance its presence in the Alzheimer's market with product launches and research endeavors, the financial adjustments appear to have dampened investor confidence.
• Contributing to the bearish sentiment could be analyst ratings like the Hold recommendation from Bank of America Securities, creating uncertainty among investors due to varying opinions.
• The stock's negative performance today reflects a market reaction influenced by financial implications and analyst assessments, despite Biogen's ongoing advancements in its pipeline and infrastructure.